{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2025:3Z74BQTJHSJA4Q4HCRRO2NHANV","short_pith_number":"pith:3Z74BQTJ","canonical_record":{"source":{"id":"2501.08410","kind":"arxiv","version":1},"metadata":{"license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","primary_cat":"stat.ME","submitted_at":"2025-01-14T19:57:18Z","cross_cats_sorted":[],"title_canon_sha256":"4469ba84196312f8d154d8fc52e47f63df339231706fa14fdfc0936e3246f592","abstract_canon_sha256":"03a28dbddbc3a1c731ad3cb5f95cd64e5eecf4fa9d8c73191be667901dbec064"},"schema_version":"1.0"},"canonical_sha256":"de7fc0c2693c920e43871462ed34e06d6a7f14639b50a21a47728d4c51a947cb","source":{"kind":"arxiv","id":"2501.08410","version":1},"source_aliases":[{"alias_kind":"arxiv","alias_value":"2501.08410","created_at":"2026-07-05T10:01:02Z"},{"alias_kind":"arxiv_version","alias_value":"2501.08410v1","created_at":"2026-07-05T10:01:02Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2501.08410","created_at":"2026-07-05T10:01:02Z"},{"alias_kind":"pith_short_12","alias_value":"3Z74BQTJHSJA","created_at":"2026-07-05T10:01:02Z"},{"alias_kind":"pith_short_16","alias_value":"3Z74BQTJHSJA4Q4H","created_at":"2026-07-05T10:01:02Z"},{"alias_kind":"pith_short_8","alias_value":"3Z74BQTJ","created_at":"2026-07-05T10:01:02Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2025:3Z74BQTJHSJA4Q4HCRRO2NHANV","target":"record","payload":{"canonical_record":{"source":{"id":"2501.08410","kind":"arxiv","version":1},"metadata":{"license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","primary_cat":"stat.ME","submitted_at":"2025-01-14T19:57:18Z","cross_cats_sorted":[],"title_canon_sha256":"4469ba84196312f8d154d8fc52e47f63df339231706fa14fdfc0936e3246f592","abstract_canon_sha256":"03a28dbddbc3a1c731ad3cb5f95cd64e5eecf4fa9d8c73191be667901dbec064"},"schema_version":"1.0"},"canonical_sha256":"de7fc0c2693c920e43871462ed34e06d6a7f14639b50a21a47728d4c51a947cb","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-07-05T10:01:02.289854Z","signature_b64":"IvdDruG+/4z3gI2lZbI8t3gQHM71CNoMfxGf6MwHVe1JHxxKZEp9a575oncpRHN8WxColf4mryyo5f+bjpraAg==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"de7fc0c2693c920e43871462ed34e06d6a7f14639b50a21a47728d4c51a947cb","last_reissued_at":"2026-07-05T10:01:02.289449Z","signature_status":"signed_v1","first_computed_at":"2026-07-05T10:01:02.289449Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"2501.08410","source_version":1,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-07-05T10:01:02Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"BsHTCjMM0/AZZK0I8JYP6xc+mVs+8x1fa7DXC0LP+nruGjmmXCxBK53X1LVZO8LlPAt5VU6RxWkGLVVZj7O4Dw==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-08-07T15:48:28.890608Z"},"content_sha256":"1fb4d9b3b55c63e5333e99875e325224a8c2bd1e2e3b51fe3b4a6a2b36236d2b","schema_version":"1.0","event_id":"sha256:1fb4d9b3b55c63e5333e99875e325224a8c2bd1e2e3b51fe3b4a6a2b36236d2b"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2025:3Z74BQTJHSJA4Q4HCRRO2NHANV","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"A Comparative Evaluation of Bayesian Model-Assisted Two-Stage Designs for Phase I/II Clinical Trials","license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","headline":"","cross_cats":[],"primary_cat":"stat.ME","authors_text":"Hao Sun, Jerry Li","submitted_at":"2025-01-14T19:57:18Z","abstract_excerpt":"The primary goal of a two-stage Phase I/II trial is to identify the optimal dose for the following large-scale Phase III trial. Recently, Phase I dose-finding designs have shifted from identifying the maximum tolerated dose (MTD) to the optimal biological dose (OBD). Typically, several doses are selected as recommended Phase II doses (RP2D) for further evaluation. In Phase II dose optimization trials, each RP2D is evaluated independently to determine its \"go/no-go\" decision. The optimal RP2D is then chosen from the remaining RP2Ds as the recommended Phase III dose (RP3D). The effectiveness of "},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2501.08410","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"integrity":{"clean":true,"summary":{"advisory":0,"critical":0,"by_detector":{},"informational":0},"endpoint":"/pith/2501.08410/integrity.json","findings":[],"available":true,"detectors_run":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938"},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-07-05T10:01:02Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"yUA+lNiw5iNhxbVdy3+tg6babWCk2GZb6pQRm7ZKJwBpCi2XMDcG84p0YvKmLKBeH70C2I9TCpNieR6mXrQ0Ag==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-08-07T15:48:28.891213Z"},"content_sha256":"3a28d59e29881f736859f20ce7013dc5d996c4cba744ebbb6a3e56ae034c9422","schema_version":"1.0","event_id":"sha256:3a28d59e29881f736859f20ce7013dc5d996c4cba744ebbb6a3e56ae034c9422"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/3Z74BQTJHSJA4Q4HCRRO2NHANV/bundle.json","state_url":"https://pith.science/pith/3Z74BQTJHSJA4Q4HCRRO2NHANV/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/3Z74BQTJHSJA4Q4HCRRO2NHANV/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-08-07T15:48:28Z","links":{"resolver":"https://pith.science/pith/3Z74BQTJHSJA4Q4HCRRO2NHANV","bundle":"https://pith.science/pith/3Z74BQTJHSJA4Q4HCRRO2NHANV/bundle.json","state":"https://pith.science/pith/3Z74BQTJHSJA4Q4HCRRO2NHANV/state.json","well_known_bundle":"https://pith.science/.well-known/pith/3Z74BQTJHSJA4Q4HCRRO2NHANV/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2025:3Z74BQTJHSJA4Q4HCRRO2NHANV","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"03a28dbddbc3a1c731ad3cb5f95cd64e5eecf4fa9d8c73191be667901dbec064","cross_cats_sorted":[],"license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","primary_cat":"stat.ME","submitted_at":"2025-01-14T19:57:18Z","title_canon_sha256":"4469ba84196312f8d154d8fc52e47f63df339231706fa14fdfc0936e3246f592"},"schema_version":"1.0","source":{"id":"2501.08410","kind":"arxiv","version":1}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"2501.08410","created_at":"2026-07-05T10:01:02Z"},{"alias_kind":"arxiv_version","alias_value":"2501.08410v1","created_at":"2026-07-05T10:01:02Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2501.08410","created_at":"2026-07-05T10:01:02Z"},{"alias_kind":"pith_short_12","alias_value":"3Z74BQTJHSJA","created_at":"2026-07-05T10:01:02Z"},{"alias_kind":"pith_short_16","alias_value":"3Z74BQTJHSJA4Q4H","created_at":"2026-07-05T10:01:02Z"},{"alias_kind":"pith_short_8","alias_value":"3Z74BQTJ","created_at":"2026-07-05T10:01:02Z"}],"graph_snapshots":[{"event_id":"sha256:3a28d59e29881f736859f20ce7013dc5d996c4cba744ebbb6a3e56ae034c9422","target":"graph","created_at":"2026-07-05T10:01:02Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"integrity":{"available":true,"clean":true,"detectors_run":[],"endpoint":"/pith/2501.08410/integrity.json","findings":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938","summary":{"advisory":0,"by_detector":{},"critical":0,"informational":0}},"paper":{"abstract_excerpt":"The primary goal of a two-stage Phase I/II trial is to identify the optimal dose for the following large-scale Phase III trial. Recently, Phase I dose-finding designs have shifted from identifying the maximum tolerated dose (MTD) to the optimal biological dose (OBD). Typically, several doses are selected as recommended Phase II doses (RP2D) for further evaluation. In Phase II dose optimization trials, each RP2D is evaluated independently to determine its \"go/no-go\" decision. The optimal RP2D is then chosen from the remaining RP2Ds as the recommended Phase III dose (RP3D). The effectiveness of ","authors_text":"Hao Sun, Jerry Li","cross_cats":[],"headline":"","license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","primary_cat":"stat.ME","submitted_at":"2025-01-14T19:57:18Z","title":"A Comparative Evaluation of Bayesian Model-Assisted Two-Stage Designs for Phase I/II Clinical Trials"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2501.08410","kind":"arxiv","version":1},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:1fb4d9b3b55c63e5333e99875e325224a8c2bd1e2e3b51fe3b4a6a2b36236d2b","target":"record","created_at":"2026-07-05T10:01:02Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"03a28dbddbc3a1c731ad3cb5f95cd64e5eecf4fa9d8c73191be667901dbec064","cross_cats_sorted":[],"license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","primary_cat":"stat.ME","submitted_at":"2025-01-14T19:57:18Z","title_canon_sha256":"4469ba84196312f8d154d8fc52e47f63df339231706fa14fdfc0936e3246f592"},"schema_version":"1.0","source":{"id":"2501.08410","kind":"arxiv","version":1}},"canonical_sha256":"de7fc0c2693c920e43871462ed34e06d6a7f14639b50a21a47728d4c51a947cb","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"de7fc0c2693c920e43871462ed34e06d6a7f14639b50a21a47728d4c51a947cb","first_computed_at":"2026-07-05T10:01:02.289449Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-07-05T10:01:02.289449Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"IvdDruG+/4z3gI2lZbI8t3gQHM71CNoMfxGf6MwHVe1JHxxKZEp9a575oncpRHN8WxColf4mryyo5f+bjpraAg==","signature_status":"signed_v1","signed_at":"2026-07-05T10:01:02.289854Z","signed_message":"canonical_sha256_bytes"},"source_id":"2501.08410","source_kind":"arxiv","source_version":1}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:1fb4d9b3b55c63e5333e99875e325224a8c2bd1e2e3b51fe3b4a6a2b36236d2b","sha256:3a28d59e29881f736859f20ce7013dc5d996c4cba744ebbb6a3e56ae034c9422"],"state_sha256":"b7f6274bdfc6f5923bb7281b9aea3cac076323ba0cc5bd4e8674c6c4efbb9241"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"FfpCuMADK1Y71m27qKsf2H+4X0r3DPgCC2D0z0RoaMJFkOy9aOExW0F4AlxRe5bJpHzrJsWrZGwI807BXCSuAA==","signed_message":"bundle_sha256_bytes","signed_at":"2026-08-07T15:48:28.914119Z","bundle_sha256":"b5221bd5794cacf3f62e417757afa48d551508210b45d349adee0330a6ea04cb"}}